ESMO 2020: Cabometyx® (cabozantinib) in combination with Opdivo® (nivolumab) demonstrates significant survival benefits in patients with advanced renal cell carcinoma in pivotal Phase III CheckMate -9ER trial
You are about to leave the events.ipsen.com website. This link is provided as a service to our website visitors. It will take you to a website maintained by a third party who is solely responsible for its content. Ipsen does not control, recommend, endorse or accept liability for sites controlled by third parties.
If you do not wish to leave this website, click Cancel. Or click Continue to continue.
You are about to leave events.ipsen.com. This link is provided as a service to our website visitors. It will take you to another website maintained by Ipsen.